Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone
PDF (Español (España))
PDF

Keywords

chronic kidney disease
peritoneal dialysis
and hypokalemia (fuente DeCS).

How to Cite

1.
Restrepo Valencia CA, Manjarrés Iglesias G, Vélez Álvarez C. Hypokalemia results of treatment for patients in peritoneal dialysis with spironolactone. Rev. Colomb. Nefrol. [Internet]. 2016 Jan. 9 [cited 2021 Dec. 7];2(2):102-10. Available from: https://www.revistanefrologia.org/index.php/rcn/article/view/210

Abstract

Objective: To determine whether a treatment with spironolactone can correct chronic idiopathic hypokalemia for patients with chronic kidney disease undergoing treatment with peritoneal dialysis.

Design: Interventional study without control group.

Patients: Patients with chronic kidney disease over 18 years old, undergoing treatment with peritoneal dialysis for over 1 year; with reported diuresis of less than 100 ml in 24 hours and in whom chronic idiopathic hypokalemia was diagnosed.

Materials and Methods: All patients were tested for known causes of hypokalemia; once these causes were discarded we initiated treatment with spironolactone with an initial dose of 25 mgs per day and a monthly increase of 25 mgs until a maximum dose of 200 mg per day. Serum potassium was measured monthly and dialyzed potassium was measured every 6 months.

Results: 20 patients fulfilled the requirements for inclusion. Four patients (20%) developed hyperkalemia and had to stop the treatment. For the remaining 16 patients initial potassium of 2,84 was measured, 6 months later it was elevated to 3,40; 3,37 after 12 months; 3,58 after 18 months and 3,9 after 22 months, these values were statistically significant (p < 0,05). 12 episodes of peritonitis occurred for the 16 patients, representing an incidence of 1 episode per 19 patients month. The average dose of spironolactone used after 3 months was 65 mgs; 67 mgs after 6 months; 75 mgs after 12 months; 60 mgs after 18 months and 68 mgs after 22 months. In the 22 months follow up, 5 (25%) patients were with drawn for motives not related to therapy and 7 of the 16 (43.75%) patients passed away.

Conclusions: Hypokalemia is a cause of great mortality for patients undergoing treatment with peritoneal dialysis; in addition to its own risks it also facilitates the development of peritonitis that requires additional therapeutic interventions. We suggest that could Spironolactone diminish the intestinal loss of  otassium but may cause hyperkalemia so patients must be closely monitored.

https://doi.org/10.22265/acnef.2.2.210
PDF (Español (España))
PDF

References

1. Szeto CC, Chow KM, Kwan BC, Leung CB, Chung KY, Law MC, et al. Hypokalemia en Chinese peritoneal dialysis patients: prevalence and prognostic implication. Am J Kidney Dis. 2005;46:128-135.

2. Khan AN, Bernardini J, Johnston JR, Piraino B. Hypokalemia in peritoneal dialysis patients. Perit Dial Int. 1996;16:652.

3. Vavruk AM, Martins C, Nascimento MM, Hayashi SY, Riella MC. Association between hypokalemia, malnutrition and mortality in peritoneal dialysis patients. J Bras Nefrol. 2012;34:349–354.

4. Tziviskou E, Musso C, Bellizzi V, Khandelwal M, Wang T, Savaj S, et al. Prevalence and pathogenesis of Hypokalemia in patients on chronic peritoneal dialysis: one center´s experience and review of the literature. Int Urol Nephrol. 2003;35:429-434.

5. Yu HL, Lu XH, Su CY, Tang W, Wang T. Potassium metabolism in continuous ambulatory peritoneal dialysis patients. Ren Fail. 2014;36:748-754.

6. Torlen K, Kalantar-Zadeh K, Molnar MZ, Vashistha T, Mehrotra R. Serum potassium and cause specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol. 2012;7:1272-1284.

7. Xu Q, Xu F, Fan L, Xiong L, Li H, Cao S, et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. Plos One. 2014;9: e86750.

8. Chuang YW, Shu KH, Yu TM, Cheng CH, Chen CH. Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis en CAPD patients. Nephrol Dial Transplant. 2009;24:1603-1608.

9. Liawnoraset W. Prevalence and factors affecting peritonitis in CAPD in Mahart Nakhon Ratchasima Hospital under universal coverage scheme during 2008-2010: a three year experience. J Med Assoc Thai. 2011;94 Suppl 4:S19-S24.

10. Shu KH, Chang CS, Chuang YW, Cheng CH, Wu MJ, Yu TM. Intestinal bacterial overgrowth in CAPD patients with hypokalaemia. Nephrol Dial Transplant. 2009;24:1289-1292.

11. Jung JY, Chang JH, Lee HH, Chung W, Kim S. De novo hypokalemia in incident peritoneal dialysis patients: a year observational study. Electrolyte Blood Press. 2009;7:73-78.

12. Factor KF. Potassium management in pediatric peritoneal dialysis patients: can diet with increased potassium maintain a normal serum potassium without a potassium supplement? Adv Perit Dial 2007;23:167-169.

13. Yi JH, Yun YW, Han SW, Kim HJ. Comparison of Icodextrin and 2,5% glucose in potassium metabolism by acute K load via dialysate in continuous ambulatory peritoneal dialysis patients. Electrolyte Blood Press. 2009;7:25-30.

14. Yi JH, Park JI, Choi HY, Lee HY, Han SW, Kim HJ. Icodextrin improves the serum potassium profile with enhancement of nutritional status in continuous ambulatory peritoneal dialysis patients. Electrolyte Blood Press. 2009;7:79-86.

15. Spital A, Sterns RH. Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6:173-176.

16. Amirmokri P, Morgan P, Bastani B. Intra-peritoneal administration of potassium and magnesium: A practical method to supplement these electrolytes in peritoneal dialysis. Ren Fail. 2007;29:603-605.

17. Rostand SG. Profound hypokalemia in continuous ambulatory peritoneal dialysis. Arch Intern Med. 1983;143:377-378.

18. Pisoni R, Acelejado MC, Cartmill FR, Dudenbostel T, Dell Ítalia LJ, Cofield SS, et al. Long term effects of aldosterone blockade en resistant hypertension associated with chronic kidney disease. Journal of Human Hypertension. 2012;26: 502-506.

19. Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G,Chen J. Effects of spironolactone on dialysis patients with refractory hypertesion. J Clin Hypertens (Greenwich). 2014:1-6.

20. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. JACC. 2014;63:528-536.

21. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S. A prospective double blind randomized placebo controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudy J Kidney Dis Transplant. 2012;23:507-512.

22. Ito Y, Mizuno M, Suzuki Y, Tamai H, Hiramatsu T, Ohashi H, et al. Nagoya Spiro Study Group. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 2014;251094-102.

23. Yongsiri S, Thammakumpee J, Prongnamchai S, Tengpraettanakorn P, Chueansuwan R, Tangjaturonrasme S, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone for Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients. Ther Apher Dial. 2014 Sep 4. doi: 10.1111/1744-9987.12219. [Epub ahead of print].

24. Musso CG, de Miguel R, Algranati L, Dos Ramos Farias E. Renal potassium excretion: Comparison between chronic renal disease patients and old people. Int Urol Nephrol. 2005;37:167-170.

25. Musso CG. Potassium metabolism in patients with chronic kidney disease (CKD), part I: patients not on dialysis (stages 3-4). Int Urol Nephrol. 2004;36:465-468.

26. Diaz IH, Giraldez T, Morales S, Hernandez G, Salido E, Canessa CM, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 is a tissue specific aldosterone target gene with prominent induction in the rat distal colon. Am J Physiol Gastrointest Liver Physiol. 2012;304:G122-G131.

27. Tomkins AM, Edmonds CJ. Electrical potential difference, sodium absorption and potassium secretion by the human rectum during carbenoxolone therapy. Gut. 1975;16:277-284.

28. Turnamian SG, Binder HJ. Regulation of active sodium and potassium transport in the distal colon of the rat. Role of the aldosterone and glucocorticoid receptors. J Clin Invest. 1989;84:1924-1929.

29. Cho JH, Musch MW, Bookstein CM, McSwine RL, Rabenau K, Chang EB. Aldosterone stimulates intestinal Na+ absorption in rats by increasing NHE3 expression of the proximal colon. Am J Physiol Cell Physiol. 1998;274: C586-C594.

30. Bergann T, Plöger S, Fromm A, Zeissig S, Borden SA, Fromm M, et al. A colonic mineralocorticoid receptor cell model expressing epithelial Na+ channels. Biochem Biophys Res Commun. 2009;382:280-285.

31. Epple HJ, Schulzke JD, Schmitz H, Fromm M. Enzyme- and mineralocorticoid receptor-controlled electrogenic Na+ absorption in human rectum in vitro. Am J Physiol. 1995;269:G42-G48.

32. Farese S, Kruse A, Pasch A, Dick B, Frey BM, Uehlinger DE, Frey FJ. Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney Int. 2009;76:877-884.

33. Hatch M, Freel RW. Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT1 receptor agonism. Am J Physiol Gastrointest Liver Physiol. 2008; 295:G348-G356.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Downloads

Download data is not yet available.